Venmax Drugs Allots 7.75 Lakh Equity Shares

Venmax Drugs and Pharmaceuticals converts warrants worth ₹1.16 crores, allotting 7,75,000 equity shares to three non-promoter investors at ₹20 per share on January 21, 2026.

Venmax Drugs Reports Strong Revenue Growth and Announces Amalgamation with Hatri Pharma

Venmax Drugs and Pharmaceuticals Limited reported revenue from operations of Rs 131.85 lakhs for the quarter ended September 30, 2025, compared to Rs 17.13 lakhs in the same quarter last year. Half-year revenue reached Rs 252.87 lakhs versus Rs 27.53 lakhs in the previous year. The company posted a profit of Rs 2.44 lakhs for the quarter compared to a loss of Rs 30.44 lakhs in the corresponding quarter last year. The Board approved financial statements as of September 30, 2025, for valuation purposes related to the proposed amalgamation with Hatri Pharma Private Limited, which was initially approved on September 2, 2025. Under the amalgamation scheme, shareholders of Hatri Pharma will receive 1 equity share of Venmax for every 1 share held in Hatri Pharma. Hatri Pharma has a net worth of Rs 1,610 lakhs and turnover of Rs 1,846.41 lakhs, while Venmax has a net worth of Rs 857.72 lakhs. The amalgamation aims to achieve operational efficiencies, cost reduction, and economies of scale through backward integration.